Single-cell studies of IFN-β promoter activation by wild-type and NS1-defective influenza A viruses

M. J. Killip, D. Jackson, M. Pérez-Cidoncha, E. Fodor and R. E. Randall

Abstract

Deletion or truncation of NS1, the principal IFN antagonist of influenza viruses, leads to increased IFN induction during influenza virus infection. We have studied activation of the IFN induction cascade by both wild-type and NS1-defective viruses at the single-cell level using a cell line expressing GFP under the control of the IFN-β promoter and by examining MxA expression. The IFN-β promoter was not activated in all infected cells even during NS1-defective virus infections. Loss of NS1 expression is therefore insufficient per se to induce IFN in an infected cell, and factors besides NS1 expression status must dictate whether the IFN response is activated. The IFN response was efficiently stimulated in these cells following infection with other viruses; the differential IFN response we observe with influenza viruses is therefore not cell specific but is likely due to differences in the nature of the infecting virus particles and their subsequent replication.

The IFN arm of the innate immune response restricts virus replication and spread during in vivo virus infections prior to activation of the adaptive immune system. Recognition of certain viral molecular structures (pathogen-associated molecular patterns, PAMPs) as non-self by pathogen recognition receptors (PRRs) enables an infected cell to detect the presence of a virus and activate the IFN induction cascade, leading to stimulation of the IFN promoter, IFN expression and secretion. IFN virus and activate the IFN induction cascade, leading to stimu-

ors (PRRs) enables an infected cell to detect the presence of a

genome segments [2, 3]; stretches of dsRNA directly adjacent

to the partially complementary termini of the influenza A virus

segments do not generally exist as free RNA but are encapsi-

ated by viral nucleoprotein (NP) and polymerase to form

ribonucleoproteins (RNPs), which are likely to impact the

ability of RIG-I to recognize viral genomes. The precise origin

of influenza virus PAMPs during infection is therefore still

unclear, and contradictory reports exist on the importance of

incoming RNPs and the requirements for viral RNA synthesis

for the induction of IFN [5, 6]. Additionally, although RIG-I

has long been considered the PRR for influenza virus, MD
d5 was recently implicated as performing a more significant role

in this process than previously thought [7]. Several distinct

PAMPs that stimulate different PRRs could therefore be gen-

erated during the course of an influenza virus infection.

Like other viruses, influenza virus encodes factors that antago-
nize the IFN response in order to be able to replicate effi-

ciently. Although other viral proteins have been reported to

modulate IFN expression [8–11], the principal of these is the

NS1 protein, which limits IFN expression at several different

stages of the IFN induction pathway and can additionally

inhibit the expression and/or function of ISG products down-

stream. As a result, viruses with NS1 deletions or truncations

induce large amounts of IFN and are attenuated in IFN-com-

petent systems [12–14]. The RNA-binding domain of NS1

has been implicated in preventing activation of the IFN-β pro-

moter during infection by sequestering dsRNA away from

PRRs, and recombinant viruses expressing RNA binding

mutants of NS1 induce higher levels of IFN than wild-type

(wt) virus [15–18]. NS1 also inhibits RIG-I and downstream

IFN induction by targeting the TRIM25 ubiquitin ligase that is

required for RIG-I activation [19–22]. Post-transcriptional

inhibition of IFN expression by NS1 additionally occurs

through the binding and inhibition of the 30 kDa subunit of

the cellular cleavage and polyadenylation specificity factor

Received 22 October 2016; Accepted 14 December 2016

Author affiliations: 1 School of Biology, Biomedical Sciences Research Complex, North Haugh, University of St. Andrews, Fife KY16 9ST, UK; 2 Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.

Correspondence: M. J. Killip, marian.killip@phe.gov.uk; R. E. Randall, rer@st-andrews.ac.uk

Keywords: influenza virus; NS1; interferon; IFN; innate immune response; interferon antagonist.

Abbreviations: ISG, interferon-stimulated gene; NP, nucleoprotein; PAMP, pathogen-associated molecular pattern; PRR, pathogen recognition receptor; RNP, ribonucleoprotein.
(CPSF30), which prevents the processing of all cellular pre-mRNA 3’-ends, thereby globally limiting the expression of host genes including IFN-β and ISGs [23–26]. The relative contribution of each of these functions towards overall limiting of IFN expression differs between virus strains, since some strains do not target CPSF30 while others are unable to prevent IFN induction upstream of the IFN promoter [26, 27].

Most previous studies examining IFN induction by influenza viruses have used methods that give an indication of the average response across a cell population; consequently, little information exists on the activation of innate immune responses to influenza virus infection at the single-cell level. In this study, we have extended our previous work into the examination of IFN induction at the single-cell level by negative-sense RNA viruses [28–30] to study IFN induction by influenza viruses in greater depth. Activation of the IFN induction cascade in individual infected cells was examined using the A549/pr(IFN-β)-GFP cell line; these human lung epithelial cells express GFP under the control of the IFN-β promoter and consequently respond very effectively to IFN inducers, including synthetic dsRNA and stocks of paramyxoviruses that are rich in defective viruses (Fig. 1a, b) [28, 30–32]. As we have reported previously [28, 29], IFN expression in cells infected with A/Udorn/72 (Udorn; H3N2) and A/Puerto Rico/8/34 (PR8; H1N1) influenza A viruses was observed only in a very low percentage of infected (i.e. NP-positive) cells (0.25 and 1.16%, respectively) (Fig. 1a). While this result clearly indicates that the majority of infected cells are negative for IFN-β.GFP expression, this does not necessarily mean that the IFN

![Graph](image-url)

**Fig. 1.** Failure to activate the IFN-β promoter by NS1-defective influenza A viruses. (a) A549/pr(IFN-β)-GFP cells were uninfected or infected with Ud wt, PR8 wt or Sendai virus (SeV) Cantell at 5 p.f.u. cell−1. At 16 h post-infection (p.i.), cells were trypsinized, fixed, permeabilized and immunostained with antibody against influenza virus NP and subsequently analysed for NP and GFP expression by flow cytometry. Cells were divided into quadrants according to intensity of NP and GFP expression, and the percentage of cells in each quadrant is indicated on each graph. (b) Cell lysates were generated from A549/pr(IFN-β)-GFP monolayers infected with Ud wt, Ud-Δ99/R38A, PR8 wt or PR8-ΔNS1 at 5 p.f.u. cell−1 or uninfected cells for 16 h p.i., then subjected to SDS-PAGE and immunoblotting with antibodies specific to phospho-IRF3, GFP, viral proteins and actin. (c) Cells were treated as in (b). IFN present in culture media was estimated by a cytopathic effect-reduction bioassay [31]. Error bars represent the results of three independent experiments. (d, e) A549/pr(IFN-β)-GFP cells were uninfected or infected with Ud-Δ99/R38A or PR8-ΔNS1 at the multiplicities indicated on the plots. At 16 h p.i., cells were trypsinized, fixed, permeabilized and immunostained for influenza virus haemagglutinin or NP expression as indicated. PIV5-VAC VM2 [32] or SeV Cantell infections were also carried out as positive controls for GFP expression. Cells were analysed by flow cytometry as in (a). (f) Cells were infected as in (d) and (e). At 16 h p.i., cells were fixed, permeabilized and immunostained for influenza virus NP, GFP, NP (red) and nuclei (stained with DAPI; grey) were visualized by confocal microscopy. Arrows denote those cells that are strongly positive for virus antigen but in which GFP cannot be detected.
induction cascade has not been activated upstream of GFP protein expression in these GFP-negative cells. In cells infected with certain strains of influenza virus, the IFN-β promoter can be activated and IFN-β pre-mRNA generated, yet mature IFN-β mRNA is not formed and IFN-β protein is not expressed due to NS1-mediated inhibition of CPSF30 activity [27]. As such, viruses that target CPSF30 (including Udorn wt) prevent expression from both constitutively active and inducible promoters, which has implications for the expression of IFN and ISGs [26]. Consistent with this, considerable IRF3 activation (an indicator of IFN induction upstream of the IFN-β promoter) can be detected by Western blot in Udorn wt-infected A549/pr(IFN-β).GFP cells, yet GFP expression cannot be detected (Fig. 1b). However, this was not the case for PR8 wt-infected cells in which IRF3 activation correlated with GFP expression (Fig. 1b), consistent with the inability of this virus to inhibit CPSF30 [26, 33–35].

Given the well-described role of NS1 in limiting IFN induction, we sought to examine the effect of deleting NS1 on expression of our IFN-β reporter by infecting A549/pr(IFN-β).GFP cells with influenza viruses that lack a functional NS1 protein. Ud-Δ99/R38A, a recombinant Udorn virus, has an R38A mutation in the RNA-binding domain that abrogates the dsRNA-binding activity of the NS1 N terminus [36, 37] and lacks most of the C-terminal effector domain of NS1 [38]. Consequently, Ud-Δ99/R38A also lacks binding sites for TRIM25 and CPSF30 [19, 23, 34],
and IRF3 activation in cells infected with Ud-Δ99/R38A therefore correlates well with GFP expression, in contrast to cells infected with the parental Udorn wt virus (Fig. 1b). PR8-ΔNS1 has a complete NS1 gene deletion in the PR8 background [12]. Consistent with a loss of IFN-antagonist activity, both Ud-Δ99/R38A and PR8-ΔNS1 induce considerably more IFN secretion from infected cell monolayers than their respective wt viruses (Fig. 1c). When activation of the IFN induction cascade by these viruses was examined by flow cytometry, infection with Ud-Δ99/R38A and PR8-Δ NS1 resulted in a higher number of GFP-positive infected cells (Fig. 1d, e) than seen for Ud wt or PR8 wt (Fig. 1a), due to alleviation of the NS1-mediated inhibition of IFN expression that exists during wt virus infections. However, strikingly, a considerable number of infected cells that were strongly positive for viral protein remained negative for GFP, indicating that the IFN induction cascade had not been activated despite viral replication occurring in these cells. In contrast, our positive controls in these experiments, paramyxovirus preparations rich in defective viruses (including the Cantell preparation of Sendai virus, which like influenza virus is known to generate RIG-I ligands [2, 39]), induced GFP in the majority of infected cells (Fig. 1a, d, f). In support of the flow cytometry data (Fig. 1d,f), Ud-Δ 99/R38A and PR8- ΔNS1-infected cells that are positive for viral protein but negative for GFP expression were also clearly seen by microscopy (Fig. 1f). This pattern of IFN-β promoter activation was not due to examination of GFP expression too early or too late in infection since it was observed over a time course of Ud-Δ99/R38A infection: by 8 h p.i., the majority of cells were positive for viral NP and GFP-positive cells could be detected in small numbers (Fig. 2). The number of GFP-positive cells peaked at 16 h p.i. and remained stable until 24 h, when cell death led to a slight drop in GFP expression due to the apoptogenic nature of the Δ99 NS1 deletion [38].

![Figure 2](image-url)

**Fig. 2.** Timecourse of GFP expression in A549/pr(IFN-β).GFP cells during infection with an NS1-defective influenza A virus. A549/pr (IFN-β).GFP cells were infected with Ud-Δ99/R38A at 5 p.f.u. cell⁻¹. At the indicated times post-infection, cells were trypsinized, fixed, permeabilized and immunostained for NP expression. GFP and NP expression were subsequently analysed by flow cytometry. The percentage of cells positive for NP and the percentage of cells positive for both NP and GFP at each timepoint are plotted. Flow cytometry plots at selected timepoints are shown below the graph.
We have clearly demonstrated that an IFN-β reporter gene is not expressed in a subpopulation of cells infected with NS1-defective influenza viruses, despite the multitude of ways in which NS1 functions to limit IFN induction during wt virus infections. We next examined expression of an endogenous marker of activation of the IFN response, the ISG product MxA, in A549/pr(IFN-β).GFP monolayers infected with PR8-ΔNS1. Basal MxA expression was low in uninfected cells but was upregulated following treatment with exogenous IFN or infection with SeV Cantell (Fig. 3). At low dilutions of PR8-ΔNS1, in regions of the cell monolayer in which several GFP-positive cells were present, the surrounding uninfected cells were MxA positive; this was consistent with IFN having been secreted from GFP-positive cells and eliciting an antiviral state in neighbouring uninfected cells. At higher dilutions of PR8-ΔNS1, fields of view containing one or two infected cells could be detected since PR8 does not undergo multi-cycle replication in tissue culture unless trypsin is added to the culture media. In fields of view containing NP-positive, GFP-positive cells at a high dilution of virus, surrounding uninfected cells were positive for MxA indicating the establishment of an antiviral state in these cells (Fig. 3: NP-positive/GFP-positive panel). In contrast, uninfected cells surrounding cells that were strongly NP positive but GFP negative were negative for MxA (Fig. 3: NP-positive/GFP-negative panel), strongly suggesting that IFN had not been secreted from these infected cells.

Using an IFN-β reporter gene system and endogenous MxA expression studies, we have demonstrated that both wt viruses and viruses lacking a functional NS1 protein, which are incapable of efficiently inhibiting IFN production and are robust activators of the IFN response in cell populations, stimulated IFN induction pathways in only a subset of infected cells. Thus, only a subset of infected cells is likely to be responsible for secreting the IFN that is detectable during both wt- and NS1-defective virus infections. A previous study used an IFN-β-luciferase mouse model to study the cell types responsible for IFN secretion in the infected mouse lung, and found that luciferase expression was restricted to relatively few epithelial cells and macrophages that had been infected with both the wt and an NS1-deletion mutant of the mouse-adapted H7N7 SC35M strain [40]. Furthermore, such differential expression has similarly been noted for ISGs, with only about 20% of cells infected with an NS1-deletion mutant of the A/Panama/2007/1999 strain going on to express ISG15 [41]. In an in vivo study by Kallfass and colleagues, differences in the susceptibility of cell types to influenza virus infection or cell-to-cell variability in the ability to mount an IFN response may have contributed
to the differential IFN-β promoter activation between cells. In the present study, these potential sources of variability have been eliminated; the subcloned A549/pr(IFN-β)-GFP reporter cell line can respond relatively uniformly to IFN inducers (Fig. 1a, d–f) [28, 30, 31]. Our data thus provide evidence that these cells are differentially mounting an IFN response due to differences in the nature of the infecting virus particles and their subsequent replication rather than cell-specific factors. Indeed, we have shown previously that different preparations of the same PR8 virus activate the IFN response to very different degrees [29].

We have demonstrated that influenza viruses that are defective in NS1, the principal IFN antagonist, have the ability to enter cells and replicate without leading to IFN induction. Other viral proteins, such as PB2 or PB1-F2, have been previously reported to inhibit IFN induction [8–11], and we cannot rule out that these proteins are actively inhibiting IFN induction downstream of PAMP recognition in cells infected with an NS1-deficient virus. However, we favour the interpretation that the replication cycle of influenza viruses is such that it is likely the virus can replicate without generating or exposing PAMPs (e.g. by replicating in the nucleus, in a different subcellular compartment to the cytoplasmic PRRs and by efficiently encapsidating the viral RNA genome and its full-length cRNA into RNP s), thereby preventing activation of the IFN response during normal virus replication (reviewed in Killip et al. [29]). Furthermore, our data do not support a significant role for incoming genomes in IFN induction, as has been reported previously [6, 42], since the majority of cells infected with NS1-defective viruses do not express markers of IFN response activation despite all cells having been exposed to incoming nucleocapsids. Interestingly, RIG-I has been reported to recognize RNPs from avian influenza viruses more readily than those from human viruses [6]; thus, species-specific differences could exist in the number of cells expressing IFN following infection with NS1-deficient viruses of human or avian origin.

Our results suggest that factors in addition to NS1 expression status determine the IFN activation status of a cell infected with influenza virus, and that the triggering of IFN induction pathways is likely to be associated with some form of aberrant replication, e.g. inefficient genome encapsidation, the generation of aberrant RNA products or the replication of defective genomes. There is accumulating evidence pointing to the involvement of the latter in this process [2, 29, 43–48], and a link between defective genomes and IFN induction is well documented for other negative-sense RNA virus families. Thus, rather than being required to limit IFN production in cells in which virus is replicating normally, the primary function of NS1 may be to limit IFN induction in the event of these aberrant replication events occurring.

Funding information
This work was supported by grants from the Wellcome Trust (grant no. 087751/A/08/Z to R. E. R.) and Medical Research Council, United Kingdom (programme grants MR/K000241/1 to E. F.). The University of St. Andrews is a charity registered in Scotland (No. SC013532).

Conflicts of interest
The authors declare that there are no conflicts of interest.

References
1. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1–47.
2. Baum A, Sachidanandum R, Garcia-Sastre A. Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci USA 2010;107:16303–16308.
3. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010;140:397–408.
4. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M et al. Differential roles of MDAS and RIG-I helicases in the recognition of RNA viruses. Nature 2006;441:101–105.
5. Killip MJ, Smith M, Jackson D, Randall RE. Activation of the interferon induction cascade by influenza a viruses requires viral RNA synthesis and nuclear export. J Virol 2014;88:3942–3952.
6. Weber M, Sediri H, Felgenhauer U, Binzen I, Bänfer S et al. Influenza virus adaptation PB2-627K modulates nucleocapsid inhibition by the pathogen sensor RIG-I. Cell Host Microbe 2015;17:309–319.
7. Benitez AA, Panis M, Xue J, Varble A, Shim J V et al. In vivo RNAi screening identifies MDAS as a significant contributor to the cellular defense against influenza A virus. Cell Rep 2015;11:1714–1726.
8. Dudek SE, Wixler L, Nordhoff C, Nordmann A, Anhalt D et al. The influenza virus PB1-F2 protein has interferon antagonistic activity. Biol Chem 2011;392:1135–1144.
9. Varga ZT, Ramos I, Hai R, Schmolke M, Garcia-Sastre A et al. The influenza virus protein PB1-F2 inhibits the induction of type I interferon at the level of the MAVS adaptor protein. PLoS Pathog 2011;7:e1002067.
10. Graef KM, Vreeke FT, Lau YF, McCall AW, Carr SM et al. The PB2 subunit of the influenza virus RNA polymerase affects virulence by interacting with the mitochondrial antiviral signaling protein and inhibiting expression of beta interferon. J Virol 2010;84:8433–8445.
11. Iwai A, Shiozaki T, Kawai T, Akira S, Kawaoaka Y et al. Influenza A virus polymerase inhibits type I interferon induction by binding to interferon beta promoter stimulator 1. J Biol Chem 2010;285:32064–32074.
12. Garcia-Sastre A, Egorov A, Matassov D, Brandt S, Levy DE et al. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology 1998;252:324–330.
13. Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998;72:6437–6441.
14. Kochs G, Koerner I, Thiel L, Kothlow S, Kaspers B et al. Properties of H7N7 influenza A virus strain SC35M lacking interferon antagonist NS1 in mice and chickens. J Gen Virol 2007;88:1403–1409.
15. Qian XY, Chien CY, Lu Y, Montelione GT, Krug RM. An amino-terminal polypeptide fragment of the influenza virus NS1 protein possesses specific RNA-binding activity and largely helical backbone structure. RNA 1995;1:948–956.
16. Newby CM, Sabin L, Pekosz A. The RNA binding domain of influenza A virus NS1 protein affects secretion of tumor necrosis factor alpha, interleukin-6, and interferon in primary murine tracheal epithelial cells. J Virol 2007;81:9469–9480.
17. Donelan NR, Basler CF, Garcia-Sastre A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces
high levels of beta interferon and is attenuated in mice. J Virol 2003;77:13257–13266.

18. Steidle S, Martínez-Sobrido L, Mordstein M, Lienenklaus S, García-Sastre A et al. Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J Virol 2010;84:12761–12770.

19. Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC et al. Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe 2009;5:439–449.

20. Guo Z, Chen LM, Zeng H, Gomez JA, Plowden J et al. NS1 protein of influenza A virus inhibits the function of intracytoplasmic pathogen sensor, RIG-I. Am J Respir Cell Mol Biol 2007;36:263–269.

21. Mibayashi M, Martínez-Sobrido L, Luo YM, Cárdenas WB, Gale M Jr et al. Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol 2007;81:514–524.

22. Opitz B, Rejaibi A, Dauber B, Eckhard J, Vinzing M et al. IFNbeta induction by influenza A virus is mediated by RIG-I which is regulated by the NS1 protein. Cell Microbiol 2007;9:930–938.

23. Twu KY, Noah DL, Rao P, Kuo RL, Krug RM. The CPSF30 binding site on the NS1A protein of influenza A virus is a potential antiviral target. J Virol 2006;80:3957–3965.

24. Noah DL, Twu KY, Krug RM. Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3′ end processing of cellular pre-mRNAs. Virology 2003;307:386–395.

25. das K, Ma LC, Xiao R, Radvansky B, Aramini J Jr et al. Structural basis for suppression of a host antiviral response by influenza A virus. Proc Natl Acad Sci USA 2008;105:13093–13098.

26. Hayman A, Comely S, Lackenby A, Murphy S, McCauley J et al. Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway. Virology 2006;347:52–64.

27. Kuo RL, Zhao C, Malur M, Krug RM. Influenza A virus strains that circulate in humans differ in the ability of their NS1 proteins to block the activation of IRF3 and interferon-β transcription. Virology 2010;408:146–158.

28. Chen S, Short JA, Young DF, Killip MJ, Schneider M et al. Hetero-cellular induction of interferon by negative-sense RNA viruses. Virology 2010;407:247–255.

29. Killip MJ, Fodor E, Randall RE. Influenza virus activation of the interferon system. Virus Res 2015;209:11–22.

30. Killip MJ, Young DF, Ross CS, Chen S, Goodbourn S et al. Failure to activate the IFN-β promoter by a paramyxovirus lacking an interferon antagonist. Virology 2011;415:39–46.

31. Killip MJ, Young DF, Gatherer D, Ross CS, Short JA et al. Deep sequencing analysis of defective genomes of parainfluenza virus 5 and their role in interferon induction. J Virol 2013;87:4798–4807.

32. Killip MJ, Young DF, Precious BL, Goodbourn S, Randall RE. Activation of the beta interferon promoter by paramyxoviruses in the absence of virus protein synthesis. J Gen Virol 2012;93:299–307.

33. Kochs G, García-Sastre A, Martínez-Sobrido L. Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol 2007;81:7011–7021.

34. Kuo RL, Krug RM. Influenza A virus polymerase is an integral component of the CPSF30-NS1A protein complex in infected cells. J Virol 2009;83:1611–1616.

35. Steidle S, Martínez-Sobrido L, Mordstein M, Lienenklaus S, García-Sastre A et al. Glycine 184 in nonstructural protein NS1 determines the virulence of influenza A virus strain PR8 without affecting the host interferon response. J Virol 2010;84:12761–12770.

36. Wang W, Riedel K, Lynch P, Chien CY, Montelione GT et al. RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. RNA 1999;5:195–205.

37. Min JY, Krug RM. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2′–5′ oligo (A) synthetase/RNase L pathway. Proc Natl Acad Sci USA 2006;103:7100–7105.

38. Jackson D, Killip MJ, Galloway CS, Russell RJ, Randall RE. Loss of the ability of the influenza A virus NS1 protein to promote apoptosis by this is not due to a failure to activate phosphatidylinositol 3-kinase (PI3K). Virology 2010;396:94–105.

39. Strähle L, Marq JB, Brini A, Hausmann S, Kolakofsky D et al. Activation of the beta interferon promoter by unnatural Sendai virus infection requires RIG-I and is inhibited by viral C proteins. J Virol 2007;81:12227–12237.

40. Kallfass C, Lienenklaus S, Weiss S, Staeheli P. Visualizing the beta interferon response in mice during infection with influenza A viruses expressing or lacking nonstructural protein 1. J Virol 2013;87:6925–6930.

41. von Recum-Knepper J, Sadowasser A, Weinheimer VK, Wolff T. Fluorescence-activated cell sorting-based analysis reveals an asymmetric induction of interferon-stimulated genes in response to seasonal influenza A virus. J Virol 2015;89:6982–6993.

42. Weber M, Gawanbacht A, Habjan M, Rang A, Borner C et al. Incoming RNA virus nucleocapsids containing a 5′-triphosphorylated genome activate RIG-I and antiviral signaling. Cell Host Microbe 2013;13:336–346.

43. Fresnig T, Pflugmacher A, Bachmann M, Peschel B, Reichl U. Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production. Appl Microbiol Biotechnol 2014;98:8999–9008.

44. Ngunjiri JM, Buchek GM, Mohni KN, Sekellück MJ, Marcus PI. Influenza virus subpopulations: exchange of lethal H5N1 virus NS for H1N1 virus NS triggers de novo generation of defective-interfering particles and enhances interferon-inducing particle efficiency. J Interferon Cytokine Res 2013;33:99–107.

45. Scott PD, Meng B, Marriott AC, Easton AJ, Dimmock NJ. Defective interfering influenza A virus protects in vivo against disease caused by a heterologous influenza B virus. J Gen Virol 2011;92:2122–2132.

46. Scott PD, Meng B, Marriott AC, Easton AJ, Dimmock NJ. Defective interfering virus proteins protects elderly mice from influenza. J Virol 2011;85:2112.

47. Péruez-Cidoncha M, Killip MJ, Oliveros JC, Asensio VJ, Fernández Y et al. An unbiased genetic screen reveals the polygenic nature of the influenza virus anti-interferon response. J Virol 2014;88:4632–4646.

48. Tapia K, Kim WK, Sun Y, Mercado-López X, Dunay E et al. Defective viral genomes arising in vivo provide critical danger signals for the triggering of lung antiviral immunity. PLoS Pathog 2013;9:e1003703.